GlassScriptPhysician profile
Yuan Zhao
NPI 1679122592
$5,263.94
in general payments reported to CMS, 2019-2025
26 companies · $2,485 in 2025
The $2,485 reported for 2025 was more than what 97% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $236 · 2023: $891 · 2024: $1,651 · 2025: $2,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,943 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,942.96 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $894.33 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $726.47 | 2022-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $506.75 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Ascensia Diabetes Care US INC. | $441.87 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $335.12 | 2025 | Yorvipath |
| Amgen INC. | $284.35 | 2024-2025 | Repatha, Repatha |
| Averitas Pharma INC. | $269.67 | 2024-2025 | Qutenza |
| Xeris Pharmaceuticals, INC. | $234.34 | 2023-2025 | Gvoke Hypopen |
| Abbvie INC. | $208.75 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $191.91 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.94 | 2025 | Jardiance |
| Tandem Diabetes Care, INC. | $158.83 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $131.74 | 2024-2025 | Korlym |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $124.71 | 2023 | Jynarque |
| Mannkind Corporation | $109.56 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $77.40 | 2023-2025 | Omnipod |
| Organon LLC | $75.00 | 2022 | |
| Medtronic, INC. | $69.85 | 2024-2025 | Minimed 780g |
| Beta Bionics, INC. | $47.34 | 2023 | Ilet Bionic Pancreas |
| Ibsa Pharma INC. | $41.92 | 2024-2025 | Licart, Tirosint, Flector |
| Rgh Enterprises LLC | $32.92 | 2025 | |
| Neurocrine Biosciences, INC. | $30.95 | 2025 | |
| Antares Pharma, INC. | $29.59 | 2024 | Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $27.31 | 2025 | |
| Kyowa Kirin, INC. | $25.54 | 2025 | |
| Amphastar Pharmaceuticals, INC. | $17.78 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuan Zhao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.